Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Urology Supplements Market Size & Share 2026-2035
Report ID: GMI9332
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Urology Supplements Market
Get a free sample of this reportWhat are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.

Urology Supplements Market Size
The urology supplements market was valued at USD 2.22 billion in 2025, is estimated to reach USD 2.40 billion in 2026, and is projected to expand at a 7.9% CAGR (2026-2035) to USD 4.73 billion by 2035. The market comprises dietary and nutritional supplements intended to support urinary tract, prostate, kidney, and bladder health across pharmacy, specialty retail, mass-market, and digital channels.
Urology Supplements Market Key Takeaways
Market Leader: Church & Dwight Co., Inc. led with over 14% market share in 2025.
Leading Players: Top 5 players in this market include Church & Dwight Co., Inc., Bayer Consumer Health, Pharmavite LLC, Natrol LLC, Reckitt Benckiser, which collectively held a market share of 42% in 2025.
Demand is broadening as consumers place greater emphasis on preventive, self-directed management of recurring urinary concerns and age-related urological symptoms. The category is also becoming less dependent on a single consumer cohort: repeat UTI purchasers remain foundational, while older male consumers, bladder-health buyers, and preventive-wellness users are creating a more diversified demand base.
GMI Analyst View
Our discussions with industry experts indicate that the urology supplements market generated USD 2.13 billion in 2024. We view that performance as evidence of an established condition-specific category entering the forecast period with resilient repeat-purchase behavior and expanding relevance across urinary, prostate, kidney, and bladder-health needs.
Urology Supplements Market Trends, Growth Drivers & GMI Forecast Outlook
The market's growth path rests on recurring condition-led demand, broader acceptance of preventive supplementation, and channels that can explain ingredient quality to consumers. Product performance will increasingly depend on whether brands translate clinical positioning into credible labels, consistent formulations, and repeat-purchase programs.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Recurring urinary-health needs support a replenishment model that differs from discretionary wellness purchases. Consumers managing recurrent symptoms often evaluate products not only on price but also on ingredient familiarity, tolerability, and perceived reliability, which favors brands able to maintain shelf availability across pharmacy and online channels. Cranberry and D-mannose lines remain important entry points, while broader urinary-support combinations enable brands to extend the basket beyond occasional use.
The prostate-health opportunity is supported by an older male consumer base that increasingly participates in supplement purchasing. Saw palmetto, beta-sitosterol, lycopene, pumpkin seed oil, and related formulations allow suppliers to position products around urinary-flow support and daily wellness without relying on a single ingredient narrative. Premiumization is most credible where dosage transparency, standardized extracts, and formulation quality reinforce the product proposition.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Europe's claim environment limits the commercial usefulness of otherwise familiar botanical ingredients. Where manufacturers cannot communicate a clear functional rationale on-pack or through compliant digital content, pharmacy staff and consumers have fewer tools to distinguish clinically positioned products from generic alternatives. EFSA's record of rejecting more than 70% of evaluated health-claim applications reinforces the need for cautious, evidence-led communication in the region. [2]European Food Safety Authority (EFSA). "Health claims." efsa.europa.eu
Formulation consistency is equally consequential for customer retention. Processing, extract sourcing, and dosage control can materially affect active-compound delivery, particularly in cranberry-based products where product format may complicate standardization. Brands that document quality controls, use recognized testing protocols, and make ingredient specifications easier to understand will be better placed to defend trust against lower-priced, less differentiated alternatives.
GMI Analyst View
We believe the category's most important transition is from broad supplement availability to evidence-led product selection. Channel expansion can accelerate trial, but durable growth depends on credible claims, dependable ingredient quality, and a consumer experience that turns a condition-triggered purchase into a trusted replenishment routine.
Urology Supplements Market Segment Analysis
By Application
Urinary Tract Infection (UTI)
The UTI segment generated USD 821M in 2025 and is projected to expand at a 7.3% CAGR (2026-2035). Within the urology supplements market, its scale reflects entrenched consumer use of cranberry, D-mannose, vitamin C, and combination products as preventive, nonprescription options for recurrent urinary-health concerns. The segment's mature repeat-purchase base gives established pharmacy brands an advantage, while transparent dosing and extract standardization remain central to protecting consumer confidence.
Prostate Health
Prostate health supplements accounted for a 29.0% share in 2025 and are projected to reach USD 1.43 billion in 2035. Demand is concentrated among men seeking accessible daily support for urinary-flow and prostate-wellness concerns, encouraging multi-ingredient formats that combine familiar botanicals with micronutrients. Growth should favor suppliers that balance credible ingredient education with products tailored to older consumers' preferred retail and digital buying journeys.
Kidney Health
The kidney health segment was valued at USD 412M in 2025 and is projected to reach USD 890M in 2035. Citrate-, magnesium-, and hydration-oriented products provide the principal commercial foundation, particularly where consumers associate dietary support with kidney-stone prevention and broader urinary wellness. Product positioning remains strongest when it is specific about ingredient role and avoids overextending into therapeutic claims.
Bladder Health
Bladder health supplements are projected to generate USD 515M by 2035 and expand at an 8.1% CAGR (2026-2035). The segment addresses an underserved consumer need, as approximately half of all women experience urinary incontinence at some point in their lives. [4]National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Bladder Control Problems: Definition & Facts." niddk.nih.gov Products featuring pumpkin seed extract, soy germ isoflavones, horsetail, and related ingredients are benefiting from less stigmatized consumer conversations about bladder control and from greater availability through mainstream retail.
By Ingredient Type
Multi-Ingredient
Multi-ingredient products held a 62.0% share in 2025 and are projected to generate USD 2.86 billion in 2035. Their position reflects consumer interest in formulations that address more than one perceived pathway, such as urinary comfort, immune support, and bladder function. This architecture also gives brands room to differentiate through standardized extracts, complementary nutrients, and premium delivery systems.
Single-Ingredient
Single-ingredient supplements are projected to account for a 39.5% share in 2035 and expand at an 8.3% CAGR (2026-2035). Their appeal is rooted in ingredient transparency: research-oriented consumers can identify the active compound and assess the rationale for use without navigating a complex label. Digital product pages and subscription models are particularly effective for explaining the role of focused ingredients such as D-mannose, saw palmetto, or magnesium citrate.
By Formulation
Capsules
Capsules accounted for a 32.0% share in 2025 and are projected to reach USD 1.39 billion in 2035. The format remains closely associated with condition-specific supplementation and is well suited to higher-potency botanical and multi-ingredient formulations. Its enduring relevance reflects both familiar consumer use and technical compatibility with active compounds that are more difficult to stabilize in alternative formats.
Softgels
Softgels are projected to generate USD 1.00 billion in 2035 and held a 22.0% share in 2025. The format is particularly relevant for lipid-soluble ingredients and oil-based extracts used in prostate-oriented formulas. Its premium perception supports its continued role in pharmacy and specialty retail, even as gummies and drink mixes capture consumers seeking more convenient daily routines.
Tablets
Tablets generated USD 401M in 2025 and are expected to represent a 16.5% share in 2035. They remain practical for compressed mineral and vitamin formulations, including products positioned around citrate and vitamin support. However, easier-to-swallow and more palatable formats are gradually reducing tablets' relative appeal among consumers who view daily supplement adherence as a lifestyle habit rather than a clinical routine.
Gummies & Chewables
Gummies and chewables are projected to reach USD 790M in 2035 and expand at an 11.5% CAGR (2026-2035). These formats lower the adherence barrier for consumers reluctant to take capsules or tablets and broaden access to younger and more lifestyle-oriented purchasers. Their growth also heightens the importance of maintaining active-ingredient integrity in matrices designed around taste, texture, and convenience.
Liquid
Liquid products generated USD 156M in 2025 and are projected to expand at an 8.4% CAGR (2026-2035). Drink mixes and other hydration-compatible products fit naturally with urinary-health positioning because they combine supplement intake with a familiar wellness ritual. Uqora's expansion of Flush Advanced+ into Target illustrates the growing retail relevance of liquid-format urinary-health products. [5]Uqora. "Uqora Launches Cutting-Edge Urinary Health Products at Target." businesswire.com
Powders
Powders are projected to reach USD 238M in 2035 and held a 5.0% share in 2025. The format serves a narrower but engaged audience seeking flexible dosing and integration with hydration or sports-nutrition routines. Its trajectory is likely to remain steady as category-wide format innovation concentrates more visibly in gummies, liquids, and capsule-based premium products.
By Distribution Channel
Brick & Mortar
Brick-and-mortar channels held a 55.0% share in 2025 and are projected to generate USD 2.27 billion in 2035. Pharmacies, supermarkets, health-food retailers, and specialty stores remain essential because consumers often value immediate availability and reassurance when purchasing products adjacent to a health concern. Leading brands are increasingly linking physical distribution with digital education and loyalty programs to preserve relevance as replenishment migrates online.
E-Commerce
E-commerce is projected to account for a 51.9% share in 2035 and expand at a 9.4% CAGR (2026-2035). The channel gives brands more space to communicate ingredient provenance, dosage, and product-selection logic than a physical shelf can provide. It also supports subscription programs that align with recurring purchasing patterns, especially for private or stigmatized concerns where discreet ordering is meaningful to consumers.
GMI Analyst View
We see segment leadership shifting toward products that reduce friction without diluting credibility. Convenient formats and digital subscriptions can improve adherence and retention, but the brands most likely to sustain that advantage will pair convenience with standardized actives, intelligible labels, and application-specific value propositions.
Urology Supplements Market Regional Analysis
North America Urology Supplements Market Analysis
North America held a 38.0% share in 2025 and is projected to reach USD 1.68 billion in 2035. The urology supplements market in the region benefits from mature pharmacy distribution, high consumer familiarity with dietary supplements, and established brands that can connect physical retail with online replenishment. The operating environment favors broad product portfolios spanning UTI prevention, prostate support, and bladder-health formulations.
United States
The United States accounted for a 33.5% share in 2025 and is projected to generate USD 1.46 billion in 2035. Its scale reflects a deep pharmacy and mass-retail infrastructure alongside a highly developed direct-to-consumer ecosystem. U.S. buyers influence product innovation and packaging decisions, particularly in cranberry, D-mannose, prostate-health, and gummy-format products.
Canada
Canada is projected to generate USD 214M in 2035 and expand at a 7.8% CAGR (2026-2035). Its pharmacy-led supplement environment provides a natural route to market for established North American brands, while e-commerce broadens access to condition-specific products outside major urban retail centers.
Europe Urology Supplements Market Analysis
Europe generated USD 579M in 2025 and is projected to reach USD 1.10 billion in 2035. Demand for botanical and condition-specific products is well established, but restrictive claim communication affects how suppliers educate consumers and differentiate formulations. Pharmacy credibility remains an important competitive asset, especially where claims restrictions elevate the value of recognized brands and professional recommendation.
Germany
Germany generated USD 127M in 2025 and is expected to hold a 5.0% share in 2035. Strong pharmacy penetration and consumer familiarity with botanical wellness products support premium positioning, although the route to market remains more dependent on trusted retail and pharmacist influence than on aggressive claim-led promotion.
United Kingdom
The United Kingdom is projected to generate USD 195M in 2035 and expand at a 6.5% CAGR (2026-2035). Consumer familiarity with supplements and a developed digital-retail base support category access, while continued attention to health-claim substantiation limits the scope for overly expansive ingredient messaging.
France
France accounted for a 4.2% share in 2025 and is projected to generate USD 173M in 2035. Its established consumer interest in plant-based wellness provides a receptive setting for cranberry and other botanical products, particularly through pharmacy channels where ingredient familiarity can compensate for constrained label communication.
Italy
Italy is projected to generate USD 155M in 2035 and held a 3.6% share in 2025. An established pharmacy channel and consumer acceptance of botanical products support steady demand, with demographic aging providing an additional foundation for prostate- and bladder-oriented formulations.
Spain
Spain generated USD 64M in 2025 and is expected to account for a 2.7% share in 2035. Digital adoption offers a meaningful route for broadening product access, though value sensitivity and a constrained claims environment continue to shape brand positioning and category recruitment.
Asia Pacific Urology Supplements Market Analysis
Asia Pacific held a 25.0% share in 2025 and is projected to expand at a 9.5% CAGR (2026-2035). The urology supplements market in Asia Pacific is supported by aging populations, expanding preventive-health spending, and rapidly improving access through pharmacies, marketplaces, and cross-border e-commerce. The region's diversity requires brands to adapt product format, price point, and communication to local buying behavior.
China
China accounted for a 7.5% share in 2025 and is projected to generate USD 426M in 2035. Aging demographics and digital commerce are expanding consumer access to prostate, urinary, and general wellness products. Brands that can establish trust through transparent ingredients and credible marketplace execution are well positioned in a market where online discovery strongly shapes category adoption.
Japan
Japan is projected to generate USD 251M in 2035 and held a 5.5% share in 2025. Its supplement-literate older population and structured functional-food environment support demand for products addressing prostate and bladder-health needs. Quality assurance and product credibility are particularly important in sustaining premium positioning.
India
India generated USD 89M in 2025 and is projected to expand at a 12.0% CAGR (2026-2035). Growing health awareness, modern pharmacy expansion, and digital access are bringing condition-specific supplements to a wider urban and secondary-city consumer base. Suppliers must balance clinically intelligible positioning with formats and price points that can support mass-market adoption.
South Korea
South Korea is projected to account for a 3.9% share in 2035 and generated USD 78M in 2025. Strong engagement with functional-health products and developed online retail infrastructure support demand for premium, condition-specific offerings, particularly in men's wellness and women's urinary-health categories.
Australia
Australia generated USD 44M in 2025 and is projected to reach USD 91M in 2035. A mature supplement culture, established pharmacy distribution, and consumer attention to quality and regulatory compliance create a favorable environment for trusted brands with well-defined urology-health propositions.
Latin America Urology Supplements Market Analysis
Latin America is projected to generate USD 303M in 2035 and expand at an 8.5% CAGR (2026-2035). Increasing health awareness, pharmacy modernization, and expanding online access are converting unmet urological-health needs into supplement demand. The region offers meaningful headroom for brands that can build trust while adapting portfolios to local affordability requirements.
Brazil
Brazil accounted for a 2.7% share in 2025 and is projected to generate USD 136M in 2035. Its comparatively developed pharmacy and health-food retail base makes it an important entry point for regional expansion. UTI-focused products are likely to remain central to consumer recruitment, with prostate and kidney-health products gaining relevance as the category matures.
Mexico
Mexico is projected to generate USD 90M in 2035 and held a 1.8% share in 2025. Pharmacy-chain growth and e-commerce penetration are widening access to condition-specific supplements, while the coexistence of value-tier and premium products requires careful portfolio segmentation.
Argentina
Argentina generated USD 16M in 2025 and is projected to expand at an 8.2% CAGR (2026-2035). Although economic volatility can affect discretionary consumer spending, formal pharmacy distribution and rising familiarity with preventive supplementation provide a base for sustained category development.
Middle East & Africa Urology Supplements Market Analysis
Middle East & Africa generated USD 112M in 2025 and is projected to expand at a 9.3% CAGR (2026-2035). Urbanization, higher preventive-health awareness, and modern retail development are increasing access to supplements across the region. Demand will be strongest where pharmacy credibility, consumer education, and e-commerce convenience converge.
Saudi Arabia
Saudi Arabia is projected to generate USD 84M in 2035 and expand at a 9.5% CAGR (2026-2035). Rising digital purchasing and national attention to preventive health support an attractive setting for trusted supplement brands, especially those able to combine credible health communication with convenient online and pharmacy access.
UAE
The UAE generated USD 25M in 2025 and is projected to account for a 1.4% share in 2035. High consumer spending on health products and a sophisticated pharmacy and specialty-retail environment support premium urology supplement positioning, while its diverse population creates demand for a broad range of product formats.
South Africa
South Africa is projected to generate USD 43M in 2035 and held a 0.9% share in 2025. Its relatively developed pharmacy channel and growing online retail base make it an important market for women's urinary-health and men's wellness formulations within sub-Saharan Africa.
GMI Analyst View
We expect regional performance to be defined less by uniform disease need than by the ability to convert that need into informed, repeat purchasing. North America retains structural strengths, Europe faces claim-communication constraints, and Asia Pacific offers the broadest path to incremental volume through localized formats, distribution, and pricing.
Urology Supplements Market Share & Competitive Landscape
The urology supplements market share structure is moderately concentrated among leading brands, with the top five companies collectively holding approximately 42% of global revenue in 2025. Established suppliers benefit from pharmacy access, brand familiarity, product breadth, and the ability to support both retail merchandising and digital replenishment. The remaining market remains open to private-label offerings, specialist brands, and direct-to-consumer entrants that can earn trust in specific applications or formats.
Church & Dwight Co., Inc., through AZO, held approximately 14% of the global market in 2025. Its leadership is reinforced by extensive U.S. pharmacy and mass-retail availability, a recognizable urinary-health brand, and a portfolio that spans cranberry, D-mannose, bladder-control, and drink-mix formats. Broad shelf placement creates a substantial access advantage in a category where immediate product availability often shapes the initial purchase.
Bayer Consumer Health held approximately 10% of the global market in 2025. Its competitive position reflects broad geographic distribution and brand recognition across pharmacy-led markets. The company is well placed to serve consumers seeking familiar healthcare brands, particularly in markets where pharmacy credibility matters more than direct-to-consumer product discovery.
Pharmavite LLC, including Nature Made and its Uqora business, held approximately 7% of the global market in 2025. The company combines ingredient-quality positioning with a digital-first urinary-health platform that is extending into physical retail. Uqora's channel development illustrates how brands can use direct consumer engagement to establish a premium proposition before pursuing wider pharmacy and mass-market distribution. [5]Uqora. "Uqora Launches Cutting-Edge Urinary Health Products at Target." businesswire.com
Natrol LLC and Reckitt Benckiser's Schiff Nutrition business complete the leading competitive group. Natrol participates primarily through value-oriented men's wellness and prostate-support products.
Reckitt Benckiser's Schiff Nutrition has its presence in women's health and pharmacy distribution supports access to urinary-health consumers. Across the competitive landscape, suppliers are differentiating through clinically recognizable actives, quality assurance, convenient formats, subscription capabilities, and stronger omnichannel execution.
Recent Industry Developments
In April 2026, Uqora expanded into Target stores nationwide and introduced Flush Advanced+, a urinary-health drink-mix product. The launch broadened the company's physical-retail reach while retaining Target.com availability for its wider portfolio, strengthening its transition from a direct-to-consumer platform to an omnichannel brand. [5]Uqora. "Uqora Launches Cutting-Edge Urinary Health Products at Target." businesswire.com
In November 2025, Uqora expanded its Walgreens presence to include In Control Bladder Support in selected retail locations. The development extended the company's brick-and-mortar bladder-health offering and reflected growing retailer interest in condition-specific products beyond the traditional UTI supplement aisle. [6]NutraIngredients. "Uqora broadens Walgreens launch of urinary health solutions with latest supplement." nutraingredients.com
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →